Physician profile
Niki Ramirez
NPI 1407587538
$2,650.91
in general payments reported to CMS, 2019-2025
19 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $486 · 2023: $1,214 · 2024: $580 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.83 |
| Education | $241.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $628.77 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $350.51 | 2023-2024 | Dupixent |
| Allergan, INC. | $292.50 | 2022 | |
| Dermavant Sciences, INC. | $231.22 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $198.99 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $170.14 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $124.50 | 2022-2023 | Taltz, Olumiant |
| Convatec INC. | $119.88 | 2025 | |
| Ucb, INC. | $110.23 | 2022-2025 | Cimzia, Bimzelx |
| Incyte Corporation | $70.10 | 2023-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $68.07 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $53.47 | 2023 | Winlevi, Absorica Ld |
| Genzyme Corporation | $44.95 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.84 | 2023 | Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.98 | 2023 | Spevigo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.43 | 2023 | Otezla |
| Organon LLC | $30.30 | 2025 | |
| Kyowa Kirin, INC. | $20.54 | 2023 | Poteligeo |
| Botanix Sb INC | $19.49 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niki Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.